Неоадъювантная химиоиммунотерапия у пациентов раком желудка с микросателлитной нестабильностью
(2023) In Voprosy Onkologii 69(2). p.275-284- Abstract
Introduction. Perioperative chemotherapy is the standard treatment for patients with locally advanced resectable gastric cancer. The prognostic relevance of MSI status in patients undergoing neoadjuvant chemotherapy remains unclear. Aim. To study the prognostic significance of MSI in gastric cancer patients undergoing perioperative CT. Materials and methods. The study included 173 patients with locally advanced gastric cancer who received perioperative therapy at the N.N. Blokhin National Medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the Mandard tumour regression score, including disease-free... (More)
Introduction. Perioperative chemotherapy is the standard treatment for patients with locally advanced resectable gastric cancer. The prognostic relevance of MSI status in patients undergoing neoadjuvant chemotherapy remains unclear. Aim. To study the prognostic significance of MSI in gastric cancer patients undergoing perioperative CT. Materials and methods. The study included 173 patients with locally advanced gastric cancer who received perioperative therapy at the N.N. Blokhin National Medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the Mandard tumour regression score, including disease-free survival (DFS) and overall survival (OS). Results. 17 (9.82 %) cases presented MSI-H. High TRG was detected in 15,17 % of patients with MSS status, 0 of 12 patients with MSI who received FLOT or FOLFIRINOX and 3 of 5 patients who received immunochemotherapy. The 6-month DFS in patients with MSS was 93 % versus 58 % in MSI-H patients who received CT and 100 % in patients from the immunochemotherapy group (p = 0.034). Conclusion. Our data show that the results of modern chemotherapy are worse in MSI-H patients compared to MSS tumors. However, the addition of nivolumab to chemotherapy improved the rate of pathological complete response (pCR) to 60 % in the MSI-H group.
(Less)
- author
- Sun, H. ; Nered, S. N. ; Tryakin, A. A. ; Bugaev, V. E. ; Stroganova, A. M. ; Kuznetsova, O. A. ; Zhong, B. LU ; Imaraliev, O. T. and Stilidi, I. S.
- organization
- alternative title
- Neoadjuvant chemoimmunotherapy for gastric cancer patients with microsatellite instability
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- gastric cancer, immunochemotherapy, immunotherapy, microsatellite instability (MSI), neoadjuvant chemotherapy
- in
- Voprosy Onkologii
- volume
- 69
- issue
- 2
- pages
- 10 pages
- publisher
- Izdatelstvo Meditsina
- external identifiers
-
- scopus:85169816467
- ISSN
- 0507-3758
- DOI
- 10.37469/0507-3758-2023-69-2-275-284
- language
- Russian
- LU publication?
- yes
- id
- da5fcf73-1b7a-47ce-bc1f-82f270d69ee1
- date added to LUP
- 2023-11-06 10:52:13
- date last changed
- 2023-11-06 10:52:13
@article{da5fcf73-1b7a-47ce-bc1f-82f270d69ee1, abstract = {{<p>Introduction. Perioperative chemotherapy is the standard treatment for patients with locally advanced resectable gastric cancer. The prognostic relevance of MSI status in patients undergoing neoadjuvant chemotherapy remains unclear. Aim. To study the prognostic significance of MSI in gastric cancer patients undergoing perioperative CT. Materials and methods. The study included 173 patients with locally advanced gastric cancer who received perioperative therapy at the N.N. Blokhin National Medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the Mandard tumour regression score, including disease-free survival (DFS) and overall survival (OS). Results. 17 (9.82 %) cases presented MSI-H. High TRG was detected in 15,17 % of patients with MSS status, 0 of 12 patients with MSI who received FLOT or FOLFIRINOX and 3 of 5 patients who received immunochemotherapy. The 6-month DFS in patients with MSS was 93 % versus 58 % in MSI-H patients who received CT and 100 % in patients from the immunochemotherapy group (p = 0.034). Conclusion. Our data show that the results of modern chemotherapy are worse in MSI-H patients compared to MSS tumors. However, the addition of nivolumab to chemotherapy improved the rate of pathological complete response (pCR) to 60 % in the MSI-H group.</p>}}, author = {{Sun, H. and Nered, S. N. and Tryakin, A. A. and Bugaev, V. E. and Stroganova, A. M. and Kuznetsova, O. A. and Zhong, B. and Imaraliev, O. T. and Stilidi, I. S.}}, issn = {{0507-3758}}, keywords = {{gastric cancer; immunochemotherapy; immunotherapy; microsatellite instability (MSI); neoadjuvant chemotherapy}}, language = {{rus}}, number = {{2}}, pages = {{275--284}}, publisher = {{Izdatelstvo Meditsina}}, series = {{Voprosy Onkologii}}, title = {{Неоадъювантная химиоиммунотерапия у пациентов раком желудка с микросателлитной нестабильностью}}, url = {{http://dx.doi.org/10.37469/0507-3758-2023-69-2-275-284}}, doi = {{10.37469/0507-3758-2023-69-2-275-284}}, volume = {{69}}, year = {{2023}}, }